Full disclosure: Toward a participatory and risk-limiting approach to neuroleptic drugs

Ethical Human Psychology and Psychiatry

Volumn 9, Issue 1, 2007, Pages 35-61

  Aderhold, Volkmar ^a,d   Stastny, Peter ^b,c  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c International Network of Treatment Alternatives for Recovery INTAR

^d NONE   (Germany)

Author keywords

Compliance; Family therapy; Neuroleptics; Psychosocial treatment; Schizophrenia; Soteria

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; RISPERIDONE;

ALGORITHM; ARTICLE; CLINICAL STUDY; COGNITIVE DEFECT; CONCEPTUAL FRAMEWORK; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUSTRY; DRUG WITHDRAWAL; FAMILY THERAPY; GRAY MATTER; HEALTH PRACTITIONER; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERPERSONAL COMMUNICATION; LONG TERM EXPOSURE; LOW DRUG DOSE; MENTAL HEALTH; MILIEU THERAPY; MORTALITY; NERVE DEGENERATION; NONHUMAN; OBESITY; PATIENT COMPLIANCE; PATIENT GUIDANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHIATRY; PSYCHOSOCIAL CARE; PSYCHOSOCIAL DEVELOPMENT; PSYCHOTHERAPIST; PSYCHOTHERAPY; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; SCHIZOPHRENIA; SCIENTIFIC LITERATURE; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT PLANNING; WEIGHT GAIN;

EID: 34147209418     PISSN: 15594343     EISSN: 19389000     Source Type: Journal    
DOI: 10.1891/152315007780493816     Document Type: Article

References (118)

1. Abi-Dargham, A., Kegeles, I., Zea-Ponece, Y., et al. (1999). Removal of endogeneous dopamine reveals elevation of D2 receptors in schizophrenia. Journal of Nuclear Medicine, 40(Suppl.), 30.
2. Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., et al. (2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences USA, 97, 8104-8109.
3. Aderhold, V., Alanen, Y. O., Hess, G., & Hohn, P. (Eds.). (2003). Psychotherapie der Psychosen - Integrative Behandlungsansätze aus Skandinavien. Germany: Psychosozial Verlag.
4. Aderhold, V., & Gottwalz, E. (2004). Family therapy and schizophrenia: Replacing ideology with openness. In J. Read, L. R. Mosher, & R. P. Bentall, Models of madness (pp. 335-348). Hove, UK: Brunner-Routledge.
5. Alanen, Y. O. (1997). Schizophrenia. Its origins and need-adapted treatment. London: Karnac.
6. Alanen, Y. O., Anttinen, E. E., Kokkola, A., Lehtinen, K., Ojanen, M., Pylkkänen, K, et al. (1990). Treatment and rehabilitation of schizophrenic psychoses. The Finnish treatment model. Nordisk Psykiatrisk Tidsskrift (Suppl. 22), 1-65.
7. Amering, M., Denk, E., Griengl, H., Sibitz, I., & Stasny, P. (1999). Psychiatric wills of mental health professionals: A survey of opinions regarding advance directives in psychiatry. Social Psychiatry and Psychiatric Epidemiology, 34, 30-34.
8. Andreasen, N. C., Moser, D. J., O'Leary, H. S., & Ho, B. C. (2005). Longitudinal changes in neurocognition during the first decade of schizophrenia illness. Schizophrenia Bulletin, 31, 348.
9. Angell, M. (2005). The truth about the drug companies: How they deceive us and what to do about it. London: Random House.
10. Baldessarini, R. J., & Tarsy, D. (1980). Dopamine and the pathophysiology of dyskinesia induced by antipsychotic drugs. Annual Review of Neuroscience, 3, 23-41.
11. Beasley, C. M., Jr., Sanger, T., Satterlee, W., Tollefson, G., Tran, P., & Hamilton, S. (1996). Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology, 124, 159-167.
12. Bleuler, M. E. (1978). The long-term course of schizophrenic psychosis. In L. C. Wynne, L. R. Cromwell, & S. Matthysse (Eds.), The nature of schizophrenia: New approaches to research and treatment (pp. 631-636). New York: Wiley.
13. Bockoven, J. S., & Solomon, H. C. (1975). Comparison of two five-year follow-up studies: 1947 to 1952 and 1967 to 1972. American Journal of Psychiatry, 132, 796-801.
14. Bola, J. R. (2006). Medication-free research in early episode schizophrenia: Evidence of long-term harm? Schizophrenia Bulletin, 32, 288-296.
15. Bola, J. R., Lehtinen, K., Aaltonen, J., Räkköläinen, V., Syvälahti, E., & Lehtinen, V. (2006). Predicting medication-free treatment response in acute psychosis: Cross-validation from the Finnish need-adapted project. Manuscript submitted for publication.
16. Bola, J. R., & Mosher, L. R. (2002). At issue: Predicting drug-free treatment response in acute psychosis from the Soteria project. Schizophrenia Bulletin, 28, 559-575.
17. Bola, J. R., & Mosher, L. R. (2003). Treatment of acute psychosis without neuroleptics: Two-year outcomes from the Soteria project. Journal of Nervous and Mental Disease, 191, 219-229.
18. Bonelli, R. M., Hofmann, P., Aschoff, A., Niederwieser, G., Heuberger, C., Jirikowski, G., et al. (2005). The influence of psychotropic drugs on cerebral cell death: Female neurovulnerability to antipsychotics. International Clinical Psychopharmacology, 20, 145-149.
19. Breggin, P. R. (1990). Brain damage, dementia and persistent cognitive dysfunction associated with neuroleptic drugs: Evidence, etiology and implications. Journal of Mind and Behavior, 11(3, 4), 425-464.
20. Breggin, P. R. (1996). Toxic psychiatry, New York: St. Martin's Press.
21. Breier, A., Su, T. P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., et al. (1997). Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences USA, 94, 2569-2574.
22. Carpenter, W. T. (1997). The risk of medication-free research. Schizophrenia Bulletin, 23, 11-18.
23. Carpenter, W. T., Jr., Buchanan, R. W., Kirkpatrick, B., & Breier, A. F. (1999). Diazepam treatment of early signs of exacerbation in schizophrenia. American Journal of Psychiatry, 156, 299-303.
24. Carpenter, W. T., McGlashan, T. H., & Strauss, J. S. (1977). The treatment of acute schizophrenia without drugs: An investigation of some current assumptions. American Journal of Psychiatry, 134, 14-20.
25. Chouinard, G., & Jones, B. D. (1980). Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics. American Journal of Psychiatry, 137, 16-22.
26. Ciompi, L. (1982). Affektlogik. Stuttgart, Germany: Klett-Cotta.
27. Ciompi, L., Kupper, Z., Aebi, E., Dauwalder, H. P., Hubschmid, T., Trütsch, K., et al. (1993). Das Pilotprojekt "Soteria Bern" zur Behandlung akuter Schizophrener. Ergebnisse einer vergleichenden prospektiven Verlaufsstudie über 2 Jahre. Nervenarzt, 64, 440-450.
28. Ciompi, L., & Müller, C. (1976). Lebenslauf und Alter der Schizophrenen. Eine katamnestische Langzeitstudie bis ins Senium. Berlin: Springer.
29. Conley, R. R., & Buchanan, R. W. (1997). Evaluation of treatment-resistant schizophrenia. Schizophrenia Bulletin, 23, 663-674.
30. Cozolino, L., Goldstein, M. J., Nuechterlein, K. H., West, K. L., & Snyder, K. S. (1988). The impact of education about schizophrenia on relatives varying in expressed emotion. Schizophrenia Bulletin, 14, 675-687.
31. Cullberg, J. (2003). Das dreidimensionale Entstehungsmodell der psychotischen Vulnerabiliät - Konsequenzen für die Behandlung. In V. Aderhold, Y. O. Alanen, G. Hess, & P. Hohn (Eds.), Psychotherapie der Psychosen - Integrative Behandlungsansätze aus Skandinavien. Gießen: Psychosozial Verlag.
32. de Haan, L., Linszen, D. H., Lenior, M. E., de Win, E. D., & Gorsira, R. (2003). Duration of untreated psychosis and outcome of schizophrenia: Delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication. Schizophrenia Bulletin, 29, 341-348.
33. Dorph-Petersen, K. A., Pierri, J. N., Perel, J. M., Sun, Z., Sampson, A. R., & Lewis, D. A. (2005). The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: A comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology, 30, 1649-1661.
34. Falloon, I. R. H. (1992). Early intervention for first episodes of schizophrenia: A preliminary exploration. Psychiatry, 55, 4-15.
35. Falloon, I. R. H., Boyd, J. L., McGill, C. W., Williamson, M., Razani, J., Moss, H. B., et al. (1985). Family management in the prevention of morbidity of schizophrenia. Clinical outcome of a two-year longitudinal study. Archives of General Psychiatry, 42, 887-896.
36. Farde, L., Wiesel, F. A., Stone-Elander, S., Halldin, C., Nordstrom, A. L., Hall, H., et al. (1990). D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Archives of General Psychiatry, 47, 213-219.
37. Fenton, S. W., Blyler, C. R., & Heinssen, R. K. (1997). Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophrenia Bulletin, 23, 637-651.
38. Frank, A. F., & Gunderson, J. G. (1990). The role of the therapeutic alliance in the treatment of schizophrenia: Relationship to course and outcome. Archives of General Psychiatry, 41, 228-236.
39. Gil-ad, I., Shtaif, B., Shiloh, R., & Weizman, A. (2001). Evaluation of the neurotoxic activity of typical and atypical neuroleptics: Relevance to iatrogenic extrapyramidal symptoms. Cellular and Molecular Neurobiology, 21, 705-716.
40. Gilbert, P. L., Harris, M. J., McAdams, L. A., & Jeste, D. V. (1995). Neuroleptic withdrawal in schizophrenic patients. Archives of General Psychiatry, 52, 173-193.
41. Goldstein, M. J. (1970). Premorbid adjustment, paranoid status and patterns of response to phenothiazine in acute schizophrenia. Schizophrenia Bulletin, 1, 24-27.
42. Goldstein, M. J., Rodnick, E. H., Evans, J. R., May, P. R., & Steinberg, M. R. (1978). Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry, 35, 1169-1177.
43. Hahlweg, K., Dürr, H., & Müller, U. (1995). Familienbetreuung schizophrener Patienten. Weinheim, Germany: Psychologie Verlags Union.
44. Harding, C. M., Brooks, G. W., Ashikaga, T., Strauss, J. S., & Breier, A. (1987a). The Vermont longitudinal study of persons with severe mental illness, I: Methodology, study sample, and overall status 32 years later. American Journal of Psychiatry, 144, 718-726.
45. Harding, C. M., Brooks, G. W., Ashikaga, T., Strauss, J. S., & Breier, A. (1987b). The Vermont longitudinal study of persons with severe mental illness: II. Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. American Journal of Psychiatry, 144, 727-735.
46. Hegarty, J. D., Baldessarini, R. J., Tohen, M., Waternaux, C., & Oepen, G. (1994), One hundred years of schizophrenia: A meta-analysis of the outcome literature. American Journal of Psychiatry, 151, 1409-1416.
47. Henderson, D. C., Nguyen, D. D., Copeland, P. M., Hayden, D. L., Borba, C. P., Louie, P. M., et al. (2005). Clozapine, diabetes mellitus, hyperlipidemia and cardiovascular risks and mortality: Results of a 10-year naturalistic study. Journal of Clinical Psychiatry, 66, 1116-1121.
48. Hoff, A., DeLisi, L. E., & Maurizio, A. (2005). Longitudinal neuropsychological findings of first-episode schizophrenia after ten years of illness. Schizophrenia Bulletin, 31, 326.
49. Hogarty, G. E., Anderson, C. M., Reiss, D. J., Kornblith, S. J., Greenwald, D. P., Ulrich, R. F., et al. (1991). Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. Archives of General Psychiatry, 48, 340-347.
50. Hogarty, G. E., Goldberg, S. C., Schooler, N. R., & Ulrich, R. F. (1974), Drug and sociotherapy in the aftercare of schizophrenic patients: Two year relapse rates. Archives of General Psychiatry, 31, 603-608.
51. Hogarty, G. E., Kornblith, S. J., Greenwald, D., DiBarry, A. L., Cooley, S., Flesher, S., et al. (1995). Personal therapy. A disorder-relevant psychotherapy for schizophrenia. Schizophrenia Bulletin, 21, 379-393.
52. Hogarty, G. E., & Ulrich, R. F. (1977). Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Archives of General Psychiatry, 34, 297-301.
53. Hogarty, G. E., & Ulrich, R. F. (1998). The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. Journal of Psychiatric Research, 32, 243-250.
54. Hugenholtz, G. W., Heerdink, E. R., Stolker, J. J., Meijer, W. E., Egberts, A. C., & Nolen, W. A. (2006). Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: Comparison with officially recommended doses. Journal of Clinical Psychiatry, 67, 897-903.
55. Johnstone, E. C., MacMillan, J. F., Frith, C. D., Benn, D. K., & Crow, T. J. (1990). Further investigation of the predictors of outcome following first schizophrenic episodes. British Journal of Psychiatry, 15, 182-189.
56. Joukamaa, M., Heliovaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006). Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry, 188, 122-127.
57. Kane, J. M., Davis, J. M., Schooler, N., Marder, S., Casey, D., Brauzer, B., et al. (2002). A multi-dose study of haloperidol decanoate in the maintenance treatment of schizophrenia. American Journal of Psychiatry, 159, 554-560.
58. Kane, J. M. (1996). Factors which can make patients difficult to treat. British Journal of Psychiatry (Suppl. 31), 10-14.
59. Kane, J. M. (1999). Management strategies for the treatment of schizophrenia. Journal of Clinical Psychiatry, 60 (Suppl. 12), 13-17.
60. Kane, J. M., Davis, J. M., Schooler, N., Marder, S., Casey, D., Brauzer, B., et al. (2002). A multi-dose study of haloperidol decanoate in the maintenance treatment of schizophrenia. American Journal of Psychiatry, 159, 554-560.
61. Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000). Relationship between dopamine D 2 occupancy, clinical response and side effects: A double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry, 157, 514-520.
62. Karon, B. P., & VandenBos, G. R. (1981). Psychotherapy of schizophrenia. The treatment of choice. New York: Aronson.
63. Laakso, A., Vilkman, H., Alakare, B., Haaparanta, M., Bergman, J., Solin, O., et al. (2000). Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. American Journal of Psychiatry, 157, 269-271.
64. Laruelle, M. (2000). The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies. Brain Research. Brain Research Reviews, 31, 371-384.
65. Laruelle, M., & Abi-Dargham, A. (2000). Dopamine in the history of the schizophrenic brain: Recent contribution of brain-imaging studies. Dialogues in Clinical Neuroscience, 2, 359-372.
66. Laruelle, M., Abi-Dargham, A., Gil, R., Kegeles, L., & Innis, R. (1999). Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biological Psychiatry, 46, 56-72.
67. Leff, J., Kuipers, L., Berkowitz, R., Eberlein-Vries, R., & Sturgeon, D. (1982). A controlled trial of social intervention in the families of schizophrenic patients. British Journal of Psychiatry, 141, 121-134.
68. Leff, J., Kuipers, L., Berkowitz, R., & Sturgeon, D. (1985). A controlled trial of social intervention in the families of schizophrenic patients: A two-year follow-up. British Journal of Psychiatry, 146, 594-600.
69. Lehmann, P. (Ed.). (2002). Psychopharmaka absetzen. Erfolgreiches Absetzen von Neuroleptika, Antidepressiva, Lithium, Carbamazepin und Tranquilizem. Berlin: Antipsychiatrieverlag.
70. Lehtinen, V., Aaltonen, J., Koffert, T., Rakkolainen V., & Syvalahti, E. (2000). Two-year outcome in first episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed? European Psychiatry, 15, 312-320.
71. Lempa, G. (1995). Zur psychoanalytischen Behandlungstechnik bei schizophrenen Psychosen. Forum der Psychoanalyse, 11, 133-149.
72. Ley, R. (1989). Improving patients' understanding, recall, satisfaction and compliance. In A. K. Broome (Ed.), Health psychology. New York: Chapman and Hall.
73. Lieberman, J. A., Strup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., et al. (2005b). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209-1223.
74. Lieberman, J. A., Tollefson, G. D., Charles, C., Zipursky, R., Sharma, T., Kahn, R. S., et al. (2005a). Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry, 62(4), 361-370.
75. Marder, S. R., Mebane, A., Chien, C.-P., Winslade, W. J., Swann, E., & Van Putten, T. A. (1983). Comparison of patients who refuse and consent to neuroleptic treatment. American Journal of Psychiatry, 140, 470-472.
76. Marder, S., van Kammen, D. P., Docherty, J. P., Rayner, J., & Bunney, W. E. (1979). Predicting drug-free improvement in schizophrenic psychosis. Archive of General Psychiatry, 36, 1080-1085.
77. Marder, S. R., Wirshing, W. C., Van Putten, T., Mintz, J., McKenzie, J., Johnston-Cronk, K., et al. (1994). Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia. Archives of General Psychiatry, 51, 280-287.
78. Martinot, J. L., Peron-Magnan, P., Huret, J. D., Mazoyer, B., Baron, J. C., Boulenger, J. P., et al. (1990). Striatal D2 dopaminergic receptors assessed with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients. American Journal of Psychiatry, 147, 44-50.
79. May, P. R., Tuma, A. H., Dixon, W. J., Yale, C., Thiele, D. A., & Kraude, W. H. (1981). Schizophrenia. A follow-up study of the results of five forms of treatment. Archives of General Psychiatry, 38, 776-784.
80. McEvoy, J. P., Hogarty, G. E., & Steingard, S. (1991). Optimal dose of neuroleptic in acute schizophrenia. Archives of General Psychiatry, 48, 739-745.
81. McGill, C., McGill, C. W., Falloon, I. R., Boyd, J. L., & Wood-Siverio, C. (1983). Family educational intervention in the treatment of schizophrenia. Hospital and Community Psychiatry, 34, 934-938.
82. McGlashan, T. H. (1988). A selective review of recent North American long-term followup studies of schizophrenia. Schizophrenia Bulletin, 14, 515-542.
83. McGlashan, T. H. (2006). Rationale and parameters for medication-free research in psychosis. Schizophrenia Bulletin, 32, 300-302.
84. McGlashan, T. H., & Fenton, W. S. (1993). Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophrenia Bulletin, 19, 71-84.
85. McGorry, P. D., Edwards, J., Mihalopoulos, C., Harrigan, S. M., & Jackson, H. J. (1996). EPPIC: An evolving system of early detection and optimal management. Schizophrenia Bulletin, 22, 305-326.
86. Milev, P., Ho, B. C., Arndt, S., & Andreasen, N. C. (2005). Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up. American Journal of Psychiatry, 162, 495-506.
87. Mosher, L. R., & Bola, J. R. (1999). Das Soteria-Projekt - Einschätzung des Affekts und Interventionsformen. In W. Machleidt, H. Haltenhof, & P. Garlipp (Eds.), Schisophrenie - eine affektive Erkrankung? (pp. 243-256). Stuttgart: Schattauer.
88. Mosher, L. R., & Burti, L. (1992): Psychiatrie in der Gemeinde. Bonn, Germany: Psychiatrie Verlag.
89. Mosher, L. R., Gosden, R., & Beder, S. (2004). Drug companies and schizophrenia. Unbridled capitalism meets madness. In J. Read, L. R. Mosher, & R. P. Bentall, Models of madness (pp. 115-130). Hove, UK: Brunner-Routledge.
90. Mosher, L. R., & Menn, A. Z. (1978). Community residential treatment for schizophrenia: Two-year follow-up. Hospital and Community Psychiatry, 29, 715-723.
91. Naber, D., & Krausz, M. (2001). Integrative Schizophrenietherapie -Behandlungsphilosophie und Intervention. Basel: Karger.
92. Nelson, A. A., Gold, B. H., Hutchinson, R. A., & Benezra, E. (1975). Drug default among schizophrenic patients. American Journal of Hospital Pharmacy, 32, 1237-1242.
93. Nordstrom, A. L., Farde, L., Eriksson, L., & Halldin C. (1995). No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone. Psychiatry Research, 61, 67-83.
94. Oosthuizen, P., Emsley, R., Turner, H. J., & Keyter, N. (2004). A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. International Journal of Neuropsychopharmacohgy, 7, 125-131.
95. Pantelis, C., & Lambert, T. J. R. (2003). Managing patients with "treatment resistant" schizophrenia. Medical Journal of Australia, 178(Suppl.), 62-66.
96. Pekkala, E., & Merinder, L. (2002). Psychoeducation for schizophrenia. Cochrane database of systematic reviews. Retrieved from http://www.cochrane.org/reviews/index.htm
97. Pietzcker, A., Gaebel, W., Köpcke, W., Linden, M., Müller, P., Müller-Spahn, F., et al. (1993). Continuous vs intermittent neuroleptic longterm treatment in schizophrenia - Results of a German multicenter study. Journal of Psychiatric Research, 27, 321-339.
98. Rappaport, M., Hopkins, H. K., Hall, K., Bellaza, T., & Silverman, J. (1978). Are there schizophrenics for whom drugs may be unnecessary or contraindicated? International Pharmacopsychiatry, 13, 100-111.
99. Razali, M. S., & Yahya, H. (1995). Compliance with treatment in schizophrenia: A drug intervention program in a developing country. Acta Psychiatrica Scandinavica, 91, 331-335.
100. Ross, C. A., & Read, J. (2004). Antipsychotic medication: Myths and facts. In J. Read, L. R. Mosher, & R. P. Bentall, Models of madness (pp. 101-113). Hove, UK: Brunner-Routledge.
101. Schäfer, I., Lambert, M., & Naber, D. (2004). Atypische Antipsychotika bei therapieresistenter Schizophrenie. Nervenarzt, 75, 79-91.
102. Schooler, N. R. (1991). Maintenance medication for schizophrenia: Strategies for dose reduction. Schizophrenia Bulletin, 17, 311-324.
103. Seikkula, J., Aaltonen, J., Alakare, B., & Haarakangas, K. (2006). Five-years experiences of first-episode nonaffective psychosis in open-dialogue approach: Treatment principles, follow-up outcomes, and two case studies. Psychotherapy and Research, 16, 214-228.
104. Sharfstein, S. S. (2005, August 19). Big pharma and American psychiatry: The good, the bad and the ugly. Psychiatric News, p. 3.
105. Silverman, J. (1975/76). Altered states of consciousness: Positive and negative outcomes. Journal of Altered States of Consciousness, 2, 295-317.
106. Tarrier, N., Lowson, K., & Barrowclough, C. (1991). Some aspects of family interventions in schizophrenia. II: Financial considerations. British Journal of Psychiatry, 159, 481-484.
107. Tienari, P. (1991). Interaction between genetic vulnerability and family environment: The Finnish adoptive family study of schizophrenia. Acta Psychiatrica Scandinavica, 84, 460-465.
108. Tienari, P., Wynne, L. C., & Läksy, K. (2003). Genetic boundaries of the schizophrenia spectrum: Evidence of the Finnish adoption study of schizophrenia. American Journal of Psychiatry, 160, 1-8.
109. Tienari, P., Wynne, L. C., Sorri, A., Lahti, I., Läksy, K., Moring, J., et al. (2004). Genotype-environment interaction in schizophrenia-spectrum disorder - Long-term follow-up study of Finnish adoptees. British Journal of Psychiatry, 184, 216-222.
110. Ukai, W., Ozawa, H., Tateno, M., Hashimoto, E., & Saito, T. (2004). Neurotoxic potential of haloperidol in comparison with risperidone: Implication of akt-mediated signal changes by haloperidol. Journal of Neural Transmission, 111, 667-681.
111. van Putten, T. (1974). Why do schizophrenic patients refuse to take their drugs? Archives of General Psychiatry, 31, 67-72.
112. van Putten, T., May, P. R. A., Marder, S. R., & Wittmann, L. A. (1981). Subjective response to antipsychotic drugs. Archives of General Psychiatry, 38, 187-190.
113. Viguera, A. C., Baldessarini, R. J., Hegarty, J. D., van Kammen, D. P., & Tohen, M. (1997). Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Archives of General Psychiatry, 54, 49-55.
114. Warner, R. (1985). Recovery from schizophrenia. London: Routledge.
115. Warner, R. (1994). Recovery from schizophrenia (2nd ed.). London: Routledge.
116. Wyatt, R. J. (1991). Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin, 17, 325-351.
117. Wyatt, R. J. (1997). Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophrenia Bulletin, 23, 3-9.
118. Yassa, R., Nastase, C., Dupont, D., & Thibeau, M. (1992). Tardive dyskinesia in elderly psychiatric patients: A 5-year study. American Journal of Psychiatry, 148, 1206-1211.